Sheppard Mullin Represents Signet Healthcare Partners in Investment in Goodwin Biotechnology
Sheppard Mullin represented Signet Healthcare Partners, a New York-based growth equity firm specializing in healthcare investments, in a significant growth capital investment in Goodwin Biotechnology, a leading contract manufacturer of monoclonal antibodies, recombinant proteins, vaccines, and Biologic Drug Conjugates including Antibody Drug Conjugates (ADCs) for early and late-stage clinical trials. The investment will be used to help Goodwin double its space available for cGMP capacity as it readies for further expansion of its biopharmaceutical manufacturing.
The Sheppard Mullin team, led by partner Shon Glusky (NY), included special Counsel Farha Chowdry and Carol Archer; and attorney Nathaniel Schlakman.
Click here to read the Goodwin Biotechnology press release.